BVNKF News and Press, Bavarian Nordic R/I Ord From 06/20/23

Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity resu...

2023-05-14 14:12:09 ET Call Start: 08:00 Call End: 08:50 Bavarian Nordic A/S (BVNKF) Q1 2023 Earnings Conference Call May 9, 2023 08:00 ET Company Participants Rolf Sorensen - Investor Relations Paul Chaplin - President & Chief Executive Officer Henri...

2023-05-09 09:49:48 ET Bavarian Nordic A/S press release ( OTCPK:BVNKF ): Q1 GAAP EPS of DKK5.10. Revenue of DKK1.25B (+290.6% Y/Y). For further details see: Bavarian Nordic A/S GAAP EPS of DKK5.10, revenue of DKK1.25B

Bavarian Nordic A/S (BVNKF) Q4 2022 Earnings Conference Call March 02, 2023, 08:00 AM ET Company Participants Rolf Sorensen - Investor Relations Henrik Juuel - Executive Vice President, CFO Paul Chaplin - President and Chief Executive Officer Conference Call Part...

Adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic as a global leader in travel vaccines Broadens development pipeline with a late-stage Chikungunya vaccine candidate with significant synergistic market opportunity in areas...

Although the latest CDC data has shown that more than 800K individuals have been immunized against monkeypox, those who are eligible to receive Bavarian Nordic's ( OTCPK:BVNRY ) Jynneos vaccine but haven't are 14 times more likely to contract the disease. The CDC found that prot...

Summary Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is reason for optimism given the current opportunities offered by Monkeypox, Ebola and Covid-19. The company is preparing for a new era of high-risk tropical infections and coronav...

Summary Bavarian Nordic will work to reach its guidance of between DKK 2.7 billion- DKK 2.9 billion ($359.8 million- $386.4 million) for the Fiscal Year 2022. I think that Bavarian Nordic's manufacturing expansion came as an afterthought as opposed to a proactive agenda that shoul...

A clinical trial sponsored by the U.S. National Institutes of Health (NIH) evaluating alternative strategies and methods for administering Bavarian Nordic's ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) monkeypox vaccine Jynneos has begun enrollment of adult volunteers. Demand for the vac...

Bavarian Nordic ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) ( BAVN ) said the EU has ordered an additional 170K doses of the company's monkeypox vaccine Imvanex which will be made available to EU Member States, Norway and Iceland. The Denmark-based company noted that the ...